Caladrius Biosciences, Inc.(NASDAQ : CLBS)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
Loading CLBS News...
Distribution Services » Wholesale Distributors
|GWW||W.W. Grainger, Inc.||-0.42%||239.63||10.4%||$129.66m|
|HDS||HD Supply Holdings, Inc.||-0.27%||40.33||1.8%||$80.36m|
|GPC||Genuine Parts Company||-0.63%||92.86||1.5%||$60.23m|
|MSM||MSC Industrial Direct Co., Inc. Class A||0.02%||100.51||4.8%||$48.71m|
|WCC||WESCO International, Inc.||-0.73%||67.75||0.6%||$35.32m|
|INT||World Fuel Services Corporation||-0.03%||35.14||3.6%||$28.05m|
|BECN||Beacon Roofing Supply, Inc.||-1.11%||48.25||2.8%||$22.34m|
|MRC||MRC Global Inc.||-0.17%||17.86||7.6%||$20.64m|
|CORE||Core-Mark Holding Company, Inc.||-0.74%||30.84||5.1%||$11.88m|
|AIT||Applied Industrial Technologies, Inc.||-0.08%||61.50||1.3%||$11.65m|
Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY.